Effect of estradiol and selected antiestrogens on pro- and antioxidant pathways in mammalian uterus

In this study, we examined the effect of 17 beta-estradiol and selected antiestrogens on uterine NADPH-oxidase activity, superoxide dismutase (SOD) activity, hydride (H.-), dienyl radical and O2 -radical generation, and membrane fluidity. NADPH oxidase activity was positively modulated in estradiol-treated animals and negatively regulated in animals that received injections of AF-45, RU-39411, tamoxifen, or ICI-182780. The SOD activity was markedly reduced in estradiol-treated animals when compared with the control animals. A positive modulation of SOD activity was observed upon treatment with AF45, RU39411, tamoxifen, and ICI 182780, though the potency varied among the individual test compounds. We observed detectable H(.-)-radical generation as evidenced from MNP H.- adduct formation in the uterine cell preparations from untreated control animals. Estradiol produced a tremendous augmentation in the superoxide radical profiles in uterine cell preparations compared to the control levels. All the other compounds that were tested significantly lowered the superoxide levels in the test set-up. AF-45, RU-39411, tamoxifen, and ICI-182780 induced varying orders of suppression of H(.-)-radical generation in the test subjects. There was a significant enhancement in membrane fluidity, hydride radical levels, and dienyl radical generation in the estradiol-treated group. All the antiestrogens did not exhibit a similar action on these parameters. RU-39411 exhibited antiestrogen-like activity in modulating hydride levels and membrane fluidity, whereas it stimulated dienyl radical generation. Thus our tests showed that the selected antiestrogens failed to show estrogen-like activity in these assays. It appears that estradiol exerts feedback control over pro- and antioxidant pathways and that markers of oxidative status could be used as a measure to evaluate the antiestrogenic activity of estradiol agonists/antagonists.

Modern antioestrogens and the coming revolution in women's health care

This review will focus on antioestrogens and selective oestrogen receptor modulators (SERMS). The more traditional SERMS, clomiphene citrate and tamoxifen, will be reviewed along with such modern drugs as raloxifene and faslodex, with emphasis upon their actions on breast, uterus, bone and lipids. The future potential of these medications, in the management of oestrogen-dependent gynaecological conditions such as endometriosis, dysfunctional uterine bleeding, fibroids and breast cancer will be discussed.

Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture

Estrogens as well as some antiestrogens have been shown to prevent bone loss in postmenopausal women. These compounds seem to inhibit bone resorption, but their anabolic effects have been less explored. In this study, bone marrow cultures were used to compare the effect of 17beta-estradiol (E2), and two triphenylethylene derivatives, tamoxifen (TAM), and FC1271a, and a benzothiophene derivative raloxifene (RAL) on differentiation of osteoblasts. All enhanced osteoblastic differentiation of 21-day cultures as indicated by increased mineralization and bone nodule formation. All, except RAL, stimulated cell proliferation during the first 6 days of the culture. However, in the presence of RAL the content of total protein was increased in 13-day cultures. SDS-PAGE and autoradiography of [14C]-proline labeled proteins revealed elevated level of the newly synthesized collagen type I. The pure antiestrogen ICI 182,780 abolished the increase of the specific activity of alkaline phosphatase by E2, TAM, and FC1271a but not the effect of RAL on protein synthesis. Our results show that E2 as well as TAM, FC1271a, and RAL stimulate bone formation in vitro but the mechanism of the anabolic action of RAL in bone clearly differs from that of E2, TAM, and FC1271a.

High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure

OBJECTIVES

Hormone replacement therapy protects from cardiovascular disease at the menopause in part by reduction of menopausal pro-atherogenic serum lipid changes. Tibolone has beneficial effects on lipids, although serum high density lipoprotein levels decrease. This study aimed primarily to establish the effects of long-term administration of tibolone on a new surrogate marker for cardiovascular disease risk, the measurement of carotid artery intima-media thickness (CIMT) using high-resolution ultrasound.

METHODS

Measurement of CIMT and assessment of carotid atherosclerotic plaques were undertaken in 31 women on tibolone and 30 voluntary controls from an ongoing open-label study of tibolone.

RESULTS

The two groups were comparable, except for mean age and prevalence of current smokers. Repeatability of CIMT measurements was acceptable (CV, 10.0%). CIMT was significantly thicker in those with atherosclerotic plaques and increased systolic blood pressure. Prevalence of plaques was raised in those who had ever smoked, and those with elevated systolic blood pressure. There was no influence of tibolone on CIMT, whether plaques were present or not.

CONCLUSIONS

This reliable technique demonstrates associations between CIMT and established risk factors. CIMT was significantly thicker in those with existing plaques. We did not demonstrate an effect of long-term tibolone use on either CIMT or prevalence of plaques.

Perturbation of fluid reabsorption in the efferent ducts of the rat by testosterone propionate, 17beta-oestradiol 3-benzoate, flutamide and tamoxifen

The regulation by oestradiol and testosterone of fluid reabsorption in the efferent ducts of the rat was investigated by determining the effects of administering the hormones and their antagonists. Untreated rats were compared to animals treated for 7 days with testosterone propionate (1 mg d(-1)), oestradiol benzoate (400 microg d(-1)), flutamide (10 mg d(-1)) or tamoxifen (1 mg d(-1)). Two procedures were used to measure perturbation of transepithelial fluid fluxes in vivo. The first procedure used cannulation of the proximal epididymal duct and micropuncture of the rete testis to compare the rate at which fluid enters and leaves the efferent ducts. Oestradiol administration increased (p < 0.001) the volume of fluid entering the epididymal duct from the efferent ducts (i.e. reduced reabsorption) while flutamide and tamoxifen decreased (p < 0.05) the amount of fluid entering the epididymal duct (i.e. increased fluid reabsorption). Testosterone did not have a statistically significant effect, although it produced a small increase in fluid reabsorption. There was some perturbation of the concentration of electrolytes and the osmotic pressure of the fluid leaving the efferent ducts, but as these were not large, it is suggested that the treatments had little effect on the basic mechanisms of osmotic water transport via solute-solvent coupling. The second procedure used to test the effect of the steroids involved microperfusing individual efferent ducts, and the results were consistent with those of the first study. Oestradiol decreased fluid reabsorption by the efferent ducts (p < 0.05), and testosterone (p < 0.05, lowest perfusion rate only), flutamide (p < 0.001) and tamoxifen (p < 0.01) increased reabsorption. The similar responses to flutamide and testosterone administration suggest that flutamide acted as an androgenic agonist by elevating systemic and luminal androgen. It is concluded that fluid reabsorption in the efferent ducts is perturbed by oestrogens and androgens. Although their actions have not been completely resolved, it is proposed that they are involved in a chronic regulation, with androgens stimulating and oestrogens suppressing fluid reabsorption by the ducts.